Factor V 1691 G-A (Leiden) polymorphism and cancer-related venous thromboembolism: A meta-analysis of published studies

Journal of B.U.ON.

Volumn 13, Issue 1, 2008, Pages 61-64

  Eroglu, Aydan ^a   Karasoy, D Sertkaya ^b   Eroglu, N ^a   Akar, N ^c  

^a Numune State Hospital   (Turkey)

^b HACETTEPE UNIVERSITY   (Turkey)

^c ANKARA UNIVERSITY   (Turkey)

Author keywords

Cancer; Factor V Leiden; Meta analysis; Thrombosis

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; DNA;

ARTICLE; CANCER PATIENT; CONFIDENCE INTERVAL; DISEASE ASSOCIATION; DNA POLYMORPHISM; EFFECT SIZE; FISHER EXACT TEST; GENE FUNCTION; HUMAN; MEDLINE; NEOPLASM; PREVALENCE; RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL; STATISTICAL SIGNIFICANCE; VENOUS THROMBOEMBOLISM;

FACTOR V; HUMANS; NEOPLASMS; POLYMORPHISM, GENETIC; VENOUS THROMBOEMBOLISM;

EID: 41549152048     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995; 85: 1504-1508.
2. Bertina RM, Koeleman BP, Koster T et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67.
3. Green KB, Silverstein RL. Hypercoagulability in cancer. Hematol Oncol Clin North Am 1996; 10: 499-530.
4. Prandoni P, Falanga A, Piccioli A. Cancer and venous thromboembolism. Lancet Oncol 2005; 6: 401-410.
5. Sifontes MT, Nuss R, Hunger SP, Wilimas J, Jacosson LJ, Manco-Johnson MJ. The factor V Leiden mutation in children with cancer and thrombosis. Br J Haematol 1997; 96: 484-489.
6. Haim N, Lanir N, Hoffman R, Haim A, Tsalik M, Brenner B. Acquired activated protein C resistance is common in cancer patients and is associated with venous thromboembolism. Am J Med 2001; 110: 91-96.
7. Ravin AJ, Edwards RP, Krohn MA, Kelley JR, Christopherson WA, Roberts JM. The factor V Leiden mutation and the risk of venous thromboembolism in gynecologic patients. Obstet Gynecol 2002; 100: 1285-1289.
8. Pihusch R, Danzl G, Scholz M et al. Impact of thrombophilic gene mutations on thrombosis risk in patients with gastrointestinal carcinoma. Cancer 2002; 94: 3120-3126.
9. Mitchell LG and the PARKA Group. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase. Cancer 2003; 97: 508-516.
10. Ramacciotti E, Wolosker N, Puech-Leao P et al. Prevalence of factor V Leiden, FII G20210A, FXIII Va134Leu and MTHFR C677T polymorphisms in cancer patients with and without venous thrombosis. Thromb Res 2003; 109: 171-174.
11. Mandala M, Curigliano G, Bucciarelli P et al. Factor V Leiden and G20210A prothrombin mutation and the risk of subclavian vein thrombosis in patients with breast cancer and central venous catheter. Ann Oncol 2004; 15: 590-593.
12. Eroglu A, Kurtman C, Ulu A, Çam R, Akar N. Factor V Leiden and PT G20210A mutations in cancer patients with and without venous thrombosis. J Thromb Haemost 2005; 3: 1323-1324.
13. Kennedy M, Andreescu ACM, Greenblatt MS et al. Factor V Leiden, prothrombin 20210A and the risk of venous thrombosis among cancer patients. Br J Haematol 2005; 128: 386-388.
14. De Lucia, De Vita F, Orditura M et al. Hypercoagulable state in patients with advanced gastrointestinal cancer: evidence for an acquired resistance to activated protein C. Tumori 1997; 83: 948-952.
15. Otterson GA, Monahan BP, Harold RN, Steinberg SM, Frame JN, Kaye FJ. Clinical significance of the FV: Q506 Mutation in unselected oncology patients. Am J Med 1996; 101: 406-412.
16. Stiakaki E, Germanakis I, Sfyridaki C, Katzilakis N, Danilatou V, Kalmanti M. Prevalence of factor V Leiden and other thrombophilic traits among Cretan children with malignancy. Pediatr Blood Cancer 2005; 44: 386-389.
17. Bloom JW, Doggen CJM, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005; 293: 715-722.
18. Hunter JE, Schmidt FL. Methods of meta-analysis correcting error and bias in research findings. London, The Publisher of Professional Social Science, 1990.
19. Sutton AJ, Abrams KR, Jones DR, Sheldon TA, Song F (Eds). Methods for meta-analysis in medical research. John Wiley and Sons, 2000, pp 20-23 and pp 218-221.
20. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995; 346: 1133-1134.
21. Antoniadi T, Hatzis T, Kroupis C, Economou-Petersen E, Petersen MB. Prevalence of factor V Leiden, prothrombin G20210A, and MTHFR C677T mutations in a Greek population of blood donors. Am J Hematol 1999; 61: 265-267.
22. Akar N, Akar E, Dalgin G, Sözüöz A, Ömürlü K, Cin S. Frequency of factor V (1691 G-A) mutation in Turkish population. Thromb Haemost 1997; 78: 1527-1528.
23. Pepe G, Rickards O, Vanegas OC et al. Prevalence of factor V Leiden mutation in non-European populations. Thromb Haemost 1997; 77: 329-331.
24. Irani-Hakime N, Tamim H, Kreidy R, Almawi WY. The prevalence of factor V R506Q mutation-Leiden among apparently healthy Lebanese. Am J Hematol 2000; 65: 45-49.
25. Fujimura H, Kambayash J, Monden M, Kato H, Miyata T. Coagulation factor V Leiden mutation may have a racial background. Thromb Haemost 1995; 74: 1381-1382.
26. Chan LC, Bourke C, Lam CK et al. Lack of activated protein C resistance in healthy Hong-Kong Chinese blood donors-Correlation with absence of Arg506-Gln mutation of factor V gene. Thromb Haemost 1996; 75: 522-523.